Seres Therapeutics Sees Unusually Large Options Volume (NASDAQ:MCRB)

Seres Therapeutics, Inc. (NASDAQ:MCRB) saw some unusual options trading on Monday. Investors acquired 3,575 call options on the company. This is an increase of approximately 102% compared to the typical daily volume of 1,771 call options.

Seres Therapeutics Price Performance

MCRB stock traded down $0.01 during midday trading on Monday, hitting $1.13. The stock had a trading volume of 1,966,009 shares, compared to its average volume of 4,460,625. The firm has a market cap of $170.38 million, a PE ratio of -1.88 and a beta of 2.02. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $2.65. The company’s 50-day moving average price is $1.04 and its 200 day moving average price is $0.90.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter in the previous year, the firm earned $0.36 earnings per share. As a group, sell-side analysts anticipate that Seres Therapeutics will post -0.95 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Friday, September 13th. Oppenheimer restated a “market perform” rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Chardan Capital restated a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th.

Insider Buying and Selling at Seres Therapeutics

In other Seres Therapeutics news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.08, for a total value of $26,438.40. Following the sale, the insider now owns 78,178 shares of the company’s stock, valued at approximately $84,432.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 28,844 shares of company stock valued at $30,104. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Seres Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Seres Therapeutics in the 1st quarter valued at about $39,000. Providence Wealth Advisors LLC lifted its stake in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics during the second quarter worth about $64,000. Virtu Financial LLC acquired a new position in shares of Seres Therapeutics during the first quarter worth about $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Seres Therapeutics during the second quarter worth about $92,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.